Phibro Animal Health raises full-year guidance after Q3 net sales rose 10% to $383 million and adjusted EBITDA climbed 11% to $60 million.
Phibro Animal Health Corporation updated its fiscal 2026 guidance, projecting net sales between $1.46 billion and $1.5 billion. Adjusted EBITDA is now expected to range from $247 million to $255 million, up from prior estimates.
The revision follows a strong third quarter, where net sales increased 10% year-over-year to $383 million. Adjusted EBITDA rose 11% to $60 million, driven by higher demand and operational efficiencies.
Management attributed the performance to robust market conditions and strategic initiatives. No immediate market reaction was disclosed in the earnings call summary.